1/30
03:28 pm
gern
TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results [Yahoo! Finance]
Low
Report
TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results [Yahoo! Finance]
1/30
06:05 am
gern
Geron (NASDAQ:GERN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Geron (NASDAQ:GERN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/29
10:59 am
gern
Geron (NASDAQ:GERN) had its "buy" rating reaffirmed by analysts at TD Cowen.
Medium
Report
Geron (NASDAQ:GERN) had its "buy" rating reaffirmed by analysts at TD Cowen.
1/28
12:02 am
gern
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) [Seeking Alpha]
Medium
Report
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) [Seeking Alpha]
1/18
12:41 pm
gern
Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive [Yahoo! Finance]
Low
Report
Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive [Yahoo! Finance]
1/14
02:21 pm
gern
Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth [Yahoo! Finance]
Low
Report
Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth [Yahoo! Finance]
1/12
08:00 am
gern
Geron Corporation Provides 2026 Financial Guidance
Medium
Report
Geron Corporation Provides 2026 Financial Guidance
1/7
04:53 am
gern
Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral [Yahoo! Finance]
Medium
Report
Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral [Yahoo! Finance]
12/19
01:32 pm
gern
Geron: From Launch Hype To Later-Line Gravity [Seeking Alpha]
Low
Report
Geron: From Launch Hype To Later-Line Gravity [Seeking Alpha]
12/18
04:30 pm
gern
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/18
03:32 am
gern
Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 [Yahoo! Finance]
Medium
Report
Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 [Yahoo! Finance]
12/11
11:50 pm
gern
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting [Yahoo! Finance]
12/11
05:42 pm
gern
Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines [Seeking Alpha]
Low
Report
Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines [Seeking Alpha]
12/11
08:27 am
gern
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation [Yahoo! Finance]
Medium
Report
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation [Yahoo! Finance]
12/11
08:00 am
gern
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Medium
Report
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
12/9
11:08 am
gern
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
12/9
11:08 am
gern
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
12/8
08:02 am
gern
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
Medium
Report
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
12/4
12:20 pm
gern
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Neutral
Report
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
11/26
09:27 am
gern
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]
Medium
Report
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]